Lantern Pharma Enrolls First Patient in Taiwan for Phase 2 Trial for Never-Smoker Lung Cancer
Following its recent expansion into Japan, Lantern Pharma has now dosed the first patient in Taiwan as part of its Phase 2 Harmonic clinical trial., evaluating LP-300 in never-smoker non-small cell lung cancer (NSCLC) patients who have relapsed after tyrosine kinase inhibitor (TKI) therapy.
This expansion into East Asia includes sites in Japan and Taiwan, regions with higher rates of never-smoker NSCLC compared to Western populations. In Taiwan, over 50% of lung cancer cases occur in never-smokers, making it a key location for the trial.
LP-300 is a disulfide small molecule designed to modulate cellular redox pathways and inhibit tyrosine kinase oncogenes like EGFR, ALK, ROS, and MET-1, which are commonly mutated in never-smoker NSCLC. Early results from the U.S. safety lead-in cohort showed an 86% clinical benefit rate and a 43% objective response rate, demonstrating LP-300's potential to improve chemotherapy outcomes.
The Harmonic trial compares LP-300 combined with chemotherapy (pemetrexed and carboplatin) to chemotherapy alone. It aims to enroll 90 patients across multiple sites, focusing on endpoints like progression-free survival and overall survival. Lantern Pharma plans to evaluate interim data after 30 clinical events.
The trial is supported by Lantern Pharma’s RADR platform, which analyzes oncology data to identify promising therapeutic candidates. This AI-powered approach identified LP-300’s potential to address chemotherapy resistance, accelerating its development into clinical trials.
Lantern Pharma expects the trial to provide critical data supporting regulatory filings and the global need for targeted therapies in this distinct patient population.
Cover photo: RichieChan
Topics: Clinical Trials
